Jeffrey Wolf submitted a preliminary, non-binding offer letter to acquire Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK) for $42.3 million on August 18, 2023. As of December 11, 2023. Jeffrey Wolf entered into an Asset and Equity Interests Purchase Agreement to acquire Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. Upon execution of the agreement, the Buyer agreed to assume at the closing of the transaction certain specified liabilities and manufacturing commitments relating to Elusys? business, currently estimated at $40 million and paid the company a cash payment of $0.5 million. The transaction is subject to regulatory approvals. Faith Charles of Thompson Hine LLP acted as legal advisor to Jeffrey Wolf. Leslie Marlow of Blank Rome LLP and Michael D. Allen of Richards, Layton & Finger, P.A. acted as legal advisor to NightHawk Biosciences, Inc.

Jeffrey Wolf completed the acquisition of Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK) on December 27, 2023.